Activation of the Wnt signaling pathway has been implicated recently in the pathogenesis of leukemia. We studied the function of epigenetic regulation of the Wnt pathway and its prognostic relevance in acute myelogenous leukemia (AML). We used a methylation-specific polymerase chain reaction approach to analyze the promoter methylation status of a panel of Wnt antagonists including sFRP1, sFRP2, sFRP4, sFRP5, DKK1 and DKK3. Aberrant methylation of Wnt antagonists was detected in four AML cell lines and in up to 64% of AML marrow samples. Treatment of the cell lines with 5-aza-2 0 -deoxycytidine induced reexpression of methylated Wnt antagonists and inactivation of the Wnt pathway by downregulating the Wnt pathway genes cyclin D1, TCF1 and LEF1 and reducing nuclear localization of b-catenin. In a subgroup of patients 60 years and younger with newly diagnosed AML and intermediate-risk cytogenetics, abnormal methylation of Wnt antagonists was associated with decreased 4-year relapse-free survival (28 vs 61%, respectively, P ¼ 0.03). Our results indicate a function of the epigenetic regulation of the Wnt pathway in predicting relapse in a subgroup of AML patients.
Introduction
Dysregulation of the Wnt signaling pathway is a hallmark of several types of tumors. [1] [2] [3] In human leukemic cells in acute myelogenous leukemia (AML), the role in leukemogenesis of the fusions proteins commonly found in AML and the constitutively activated mutations of the fms-like tyrosine kinase-3 (FLT3) gene is mediated in part through the activation of Wnt signaling. 4, 5 Activation of the canonical Wnt pathway results in hypophosphorylation and the stabilization of b-catenin. After translocation in the nucleus, nonphosphorylated b-catenin associates with the T-cell factor (TCF)/lymphoid-enhancing factor (LEF) family of transcription factors, which modulate the expression of target genes such as c-Myc and cyclin D. 6 This signaling pathway is regulated tightly by members of several families of secreted antagonists that interfere with ligandreceptor interactions, such as members of the secreted frizzled-related protein (sFRP) family and the Dickkopf (DKK) family. 7 Different molecular mechanisms have been implicated in the abnormal activation of the Wnt pathway. The functional loss of Wnt antagonists contributes to the activation of the Wnt pathway and results in carcinogenesis through deregulation of cell proliferation and differentiation. Transcriptional repression by promoter methylation affects Wnt antagonists in several human malignancies, including leukemia. [8] [9] [10] [11] Interestingly, DKK1 is silenced frequently by methylation in the core-binding factor (CBF) leukemias. 12 In addition, four of the five known sFRP genes are downregulated by promoter hypermethylation in AML. 13 It can be speculated that the functional loss of Wnt antagonists by promoter hypermethylation is one possible mechanism contributing to activation of the Wnt pathway in AML and that this loss may be involved in the pathogenesis and prognosis of the disease. This hypothesis has never been previously explored in AML.
We analyzed the function of aberrant gene methylation of the sFRP1, sFRP2, sFRP4, sFRP5, DKK1 and DKK3 genes in the activation of the canonical Wnt signaling pathway in AML. We also evaluated the implication of the epigenetic regulation of these Wnt antagonists and their functional role in AML.
Materials and methods

Cell lines and patient samples
Four AML-derived cell lines (Kasumi-1, KG1a, HL-60 and THP-1) were purchased from DSMZ (Deutsche Sammlung von Microorganismen und Zellkulturen GmbH, Braunschweig, Germany). Cells were grown at 37 1C under 5% CO 2 in humidified air in RPMI 1640 medium with glutamine supplemented (Gibco-BRL, Burlington, Ontario, Canada) with 20% fetal bovine serum (Gibco, Grand Island, NY, USA) and 1% penicillin/streptomycin.
The study population included 184 consecutive patients (110 men, 74 women) who were diagnosed with de novo non-M3 AML between September 1998 and March 2007 at the Hospital Universitario La Fe of Valencia, Spain. Approval was obtained from the institutional review board. Informed consent was provided according to the Declaration of Helsinki Principles. The diagnosis was made according to the morphologic and cytochemical criteria of the French-American-British (FAB) classification. 14 The median age at diagnosis was 60 years (range, 16-92 years). The median follow-up of the series was 46 months. The main clinical characteristics of the patients are listed in Table 1 . Fitted patients were enrolled into intensive chemotherapy trials in which induction therapy comprised standard combinations of anthracycline plus cytarabine. Patients achieving complete remission (CR) proceeded to consolidation therapy and eligible patients were selected for autologous or allogeneic stem cell transplantation (SCT). A total of 58 patients received SCT (25 autologous, 33 allogeneic). Total 51 patients from the whole series relapsed, and 37 remain alive.
Cytogenetic and molecular analyses
Karyotype analysis was performed using unstimulated shortterm cultures according to the recommendations of the International System for Human Cytogenetic. 15 Whenever possible, at least 20 metaphases were evaluated. Cytogenetic risk groups were defined as follows: high risk, -5/del(5q), -7/ del(7q), abn 3q, complex aberrations (X3 independent aberrations), t(9;22) and t(6;9); low risk, t(8;21) and inv (16) intermediate risk, all other karyotypic aberrations or a normal karyotype.
FLT3 internal tandem duplications (ITD) and nucleophosmin gene mutations (NPM1) were studied in cDNA samples following the methods described by Nakao et al. 16 and Schnittger et al., 17 respectively.
Methylation-specific polymerase chain reaction
High molecular weight genomic DNA was isolated from bone marrow aspirates at diagnosis using a standard protocol. DNA was treated with bisulfite to convert unmethylated cytosine to uracil using commercially available kit (EpiTect Bisulfite kit; Qiagen, Hilden, Germany) according to the manufacturer's instruction. 18 After DNA bisulfite treatment, the methylationspecific polymerase chain reaction (MSP) for sFRP1, sFRP2, sFRP4, sFRP5, DKK1 and DKK3 promoter methylation was performed. The primers for the methylated (M) and unmethylated (U) promoter regions were as reported. 8, 12, 19 Efficiencies (E) of each gene were calculated from the slopes of crossover points (Cp) vs DNA concentration plot, according to the formula E ¼ 10(À1/slope). DCp corresponded to the difference between the control/calibrator Cp and sample Cp, for either the target or reference sequences. The selected controls/ calibrators were mononuclear bone marrow cells from healthy donors. The controls/calibrators were considered as having 100% expression.
Treatment with 5-aza-2
0 -deoxycytidine Acute myelogenous leukemia-derived Kasumi-1, KG1a, HL-60 and THP-1 cell lines were cultured at a density of 0.5 Â 10 6 cells per ml in 10 ml of RPMI 1640 medium with glutamine supplemented with 10% fetal bovine serum, and maintained at 37 1C in a humid atmosphere containing 5% CO 2 . Cells were treated during 4 days with 2 mM 5-Aza-2 0 -deoxycytidine (DAC; Sigma, Taufkirchen, Germany), added daily. After treatment, cells were washed, and pelleted to isolate DNA and RNA using 1 Â 10 7 cells per ml. Cultures were always confirmed in three independent assays. 
25 (24) 20 (25) M2 27 (26) 21 (26) M4 19 (18) 7 (9) M5 16 (15) 11 (14) M6 6 (6) 12 (15) M7 1 (1) (17) 13 (16) NPM1 13 (12) 14 (17) Abbreviations: F, female; FAB, French-American-British; M, male; NS, not significant; WBC, white blood cell.
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Western blotting
The localization of b-catenin in nuclear and cytoplasmic protein extracts of the THP-1 cells was determined by western blot analysis as previously described 9 using the following antibodies: b-catenin (1:1000; Transduction Laboratories, Lexington, KY, USA) and the antibodies against lamin A (1:5000; Transduction Laboratories) and b-tubulin (1:5000; Sigma-Aldrich, St Louis, MO, USA) used to confirm equal loading of nuclear and cytoplasmic extracts, respectively.
Cell-cycle analysis
Cell-cycle profiles were determined by analyzing DNA content using propidium iodide staining and flow cytometry. 
Statistical analysis
For statistical purposes, AML patients were classified into two methylation groups according to the number of methylated Wnt antagonist genes: group A (0-1 methylated genes) and group B (X2 methylated genes). All descriptive statistics and tests (MannWhitney nonparametric U-test, w 2 -test and Fisher's exact test) were performed using the statistical package SPSS, version 11.0 (SPSS Inc., Chicago, IL, USA). Po0.05 was considered significant. Unadjusted time-to-event analysis was performed using the Kaplan-Meier method 20 and log-rank tests for comparisons. 21 CR and resistant disease were defined according to the recommendations of Cheson et al. 22 Overall survival (OS) was measured from the time of diagnosis to the time of last followup or death from any cause. Disease-free survival (DFS) and relapse-free survival (RFS) were measured from the date of CR. In the analysis of DFS, relapse or death, whichever occurred first, was considered an uncensored event. For RFS, relapse was considered an uncensored event. All P-values reported are two sided. Multivariate analysis was performed using the Cox proportional hazards model. The follow-up of the patients was updated on June 2008, and all follow-up data were censored at that point.
Results
Methylation of Wnt antagonists in AML cell lines
Hypermethylation of the Wnt antagonists was not observed in all cell lines. sFRP1, sFRP2 and DKK1 were methylated in all cell lines, sFRP5 in three cell lines, sFRP4 in one cell line and DKK3 was not methylated in any cell line (Figure 1 ). To determine whether aberrant methylation could be reverted in vitro, we treated the cell lines with the demethylating agent DAC and analyzed the expression of the genes after 4 days of treatment. Expression of all Wnt antagonists that were methylated aberrantly was upregulated indicating that hypermethylation is a major mechanism by which the expression of Wnt antagonists is silenced in AML cells (Figure 2a) . To know the specificity of the drug to induce demethylation, we treated THP-1 cells with different concentrations of DAC: 0.5, 1, 2 and 5 mM for 4 days. We observed a dose-dependent increase in the expression levels of the genes previously methylated in the THP-1 cells: sFRP1, sFRP2, sFRP5 and DKK1 (Figure 2b ).
Methylation of Wnt antagonists in AML patients
Hypermethylation of the gene promoters was observed in all six genes in the 184 AML patients. The methylation frequencies were as follows: 41% for sFRP1, 32% for DKK1, 31% for sFRP2, 22% for sFRP5, 16% for DKK3 and 4% for sFRP4 (Figures 3a and  b) . A total of 118 (64%) patients had methylation of at least one of these six Wnt antagonists. After classifying patients according to the number of methylated genes observed in each individual sample, 104 patients (57%) were included in group A (0-1 methylated gene) and 80 patients (43%) in group B (X2 methylated genes). Aberrant methylation of any individual gene was not associated with age, sex, white blood cell count, FAB classification, cytogenetic risk group, or FLT3 or NPM1 mutations. The exception was for aberrant methylation of sFRP5, which was detected more frequently in patients with adverse cytogenetics (P ¼ 0.015; data not shown). None of these clinical-biological variables differed significantly between groups A and B.
Changes in the expression level of Wnt downstream genes
To investigate the consequence of aberrant methylation of Wnt antagonists in the regulation of the Wnt pathway in AML, we also analyzed the expression of downstream signaling components of the Wnt pathway. Treatment of the AML cell lines with DAC caused downregulation of the expression of cyclin D1, TCF1 and LEF1 genes compared with cell cultures without DAC treatment (Figure 4a ). In addition, western blot showed a reduction of b-catenin in the nuclear localization, indicating the inactivation of the Wnt pathway after treatment with DAC ( Figure 4b ). As expected, the transcript levels of cyclin D1 (mean N, 136±51 vs 16±3%, P ¼ 0.045; Figure 5a ), TCF1 (mean N, 120 ± 60 vs 35 ± 4%, P ¼ 0.02; Figure 5b ) and LEF1 (mean N, 250 ± 30 vs 35 ± 7%, P ¼ 0.02; Figure 5c ) were significantly higher in group B than in group A. 
Cell-cycle regulation by DAC
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Prognostic impact of the hypermethylation of Wnt antagonists
A total of 159 patients (86%) were eligible for intensive therapy. Among them 92 patients (58%) achieved CR: 82 after one course of induction therapy and 10 after a second cycle. Evaluation of the effect of the methylation status of the individual Wnt antagonists on response to induction therapy showed that only sFRP5 was associated with resistant disease (17% in patients with unmethylated vs 40% in patients with methylated sFRP5, P ¼ 0.015). However, the number of genes methylated did not influence the CR rate; the CR rate was slightly but nonsignificantly higher in group A (64%) than in group B (51%, P ¼ 0.2) ( Table 2 ). The estimated probabilities of OS, DFS and RFS at 4 years for the whole series were 20, 20 and 46%, respectively. Univariate analysis showed that OS and DFS were significantly influenced 
P a t i e n t 2 P a t i e n t 3 P a t i e n t 4 P a t i e n t 5 C -p o s C -n e g H by age over 60 years (Po0.0001 for both) and cytogenetic risk group (P ¼ 0.004 and 0.02, respectively). In contrast, FLT3-ITD mutations were accompanied by a worse RFS (P ¼ 0.02). Evaluation of the prognostic impact of epigenetic aberrations showed that the methylation profile had a significant impact on OS at 4 years; OS was 26% in group A and 10% in group B (P ¼ 0.002). The methylation profile had no effect on DFS or RFS when the whole series was considered. By contrast, when the analysis was restricted to patients 60 years and younger with intermediate-risk cytogenetics, compared with group A patients, group B patients had significantly lower OS (25 vs 53%, P ¼ 0.01), DFS (18 vs 48%, P ¼ 0.02) and RFS (28 vs 61%, P ¼ 0.03) at 4 years ( Figure 7) .
Multivariate modeling in the global series including age, sex, FAB subtype, leukocytosis, cytogenetic risk group, FLT3 mutations and the methylation profile showed that age over 60 years, cytogenetics and FLT3 mutations were independent prognostic factors for OS and DFS, whereas age over 60 years and FLT3 mutations were accompanied by a lower RFS (Table 3) . For patients 60 years and younger with intermediate-risk cytogenetics, multivariate analysis showed that the FLT3 mutations and the methylation profile were both independent adverse prognostic factors for RFS (Table 3) .
Discussion
This study shows that the methylation status of Wnt antagonists is associated with poor prognosis in patients with AML and Abbreviations: CR, complete remission; NS, not significant; SCT, stem cell transplantation.
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suggests that methylation is a molecular mechanism responsible for the activation of the Wnt signaling pathway in AML. The adverse prognosis for patients with more than two methylated Wnt antagonists was particularly significant in patients aged 60 years and younger with intermediate-risk cytogenetics. Deregulated Wnt signaling is involved in tumor formation in several cell types, mainly in colon and hepatocellular carcinomas.
1,2 Because of the role of the Wnt pathway in survival, proliferation and differentiation of hematopoietic stem cells, it has been hypothesized that an aberrant Wnt signaling pathway also contributes to the pathogenesis of leukemia. [23] [24] [25] The Wnt signaling pathway may be an important target in several leukemogenic pathways supporting self-renewal and proliferation of AML cells. For example, transfected U937 cells with chromosomal translocations, such as t(15;17) and t(8;21), strongly induce plakoglobin, a co-activator of TCF and LEF transcription factors, and mediate activation of Wnt signaling. 4 Activating FLT3 mutations is associated with aberrant Wnt signaling in AML by inducing tyrosine phosphorylation of b-catenin and its nuclear localization. 5, 26 However, some AML patients do not harbor chromosomal translocations or FLT3 mutations but still show aberrant Wnt signaling, suggesting mechanisms of Wnt signaling activation in AML independent from these aberrations. 27, 28 In leukemia, promoter hypermethylation of CpG islands in the promoter region is an epigenetic pathway that appears to be common to several genes involved in cell-cycle control and signaling. 29, 30 Some studies have found that abnormal methylation of Wnt antagonists is a frequent event in AML. The Wif1 promoter is methylated preferentially in acute promyelocytic leukemia but not in other subtypes of AML and might be an independent indicator of poor prognosis. 16 Aberrant methylation and downregulation of sFRP1, 2, 3 and 4, and DKK1 have been reported recently in AML patients. 12, 13 However, none of these studies has demonstrated an association between the methylation status of Wnt antagonists and activation of the Wnt pathway. In our series, about 64% of the AML patients had methylation of at least one of the six genes studied; indicating that methylation of these soluble Wnt antagonists is a frequent event in patients diagnosed with AML. Of the 118 patients with methylation of at least one of these genes, 80 (43%) had methylation of two or more genes (group B).
We found some differences in the frequency of aberrant methylation of Wnt antagonists in AML patients from those reported by other groups. 12, 13 Although sFRP1, sFRP2, sFRP5 and DKK1 were methylated most frequently, as in other published series, the percentages of patients were higher in our study. Apart from the association between adverse cytogenetics and sFRP5 methylation, we found no association between gene hypermethylation and clinical characteristics. Patients with methylated sFRP5 also had a significantly higher resistance to induction therapy probably because its relationship with adverse cytogenetics. Interestingly, Veeck et al. 31 showed recently that epigenetic inactivation of sFRP5 is associated with unfavorable prognosis in breast cancer patients. Because sFRP5 was first isolated as a gene associated with apoptosis 32 and because it is more upregulated of any other sFRP when cells are treated with activators of Wnt signaling, 33, 34 sFRP5 might provide valuable information about poor outcome in AML.
Contrary to other studies, we found no association between methylation of Wnt antagonists and favorable leukemias. Two studies reported an association between methylation of Wnt 12 suggested a possible association between shorter survival and DKK1 promoter hypermethylation in CBF leukemias (n ¼ 6). A more recent study found a significant correlation between sFRP2 methylation and inferior survival in this subgroup (n ¼ 16). 13 Our study included 15 patients with CBF leukemia, but we found no correlation with the methylation status of any of the Wnt antagonists. These discrepant results probably reflect the small number of patients and different patient selection.
Román-Gó mez et al. 9 recently provided strong evidence of a relationship between hypermethylation of natural Wnt antagonists and activation of Wnt signaling in acute lymphoblastic leukemia. Although, aberrant methylation of Wnt antagonists has been described in patients with AML, 12, 13 to the best of our knowledge, our report is the first evidence that epigenetic regulation also contributes to activation of the Wnt pathway in AML. Analysis of the expression of downstream signaling components of the Wnt pathway showed upregulation of the transcription factors TCF1 and LEF1 and the Wnt target gene cyclin D1 in group B patients. DAC treatment of the AML cell lines induced a reduction of b-catenin in the nuclear localization and downregulated the expression of these factors, whereas methylated genes transcripts were reexpressed as a consequence of the demethylating treatment. Our results show that aberrant promoter methylation of Wnt antagonists results in gene silencing and might account for the activation of the Wnt pathway in AML. As cyclin D1 is involved in cell-cycle progression we also performed a FACS analysis of THP-1 cells treated with DAC to know the cellular effects of the downregulation of the expression of cyclin D1 in cell-cycle regulation. Despite cyclin D1 gene was downregulated by DAC, there was no G 1 /G 0 block, but a G 2 /M block was still detectable, as reported by others who have used DAC. 35, 36 It is reasonable to suppose that other genes/ proteins are affected by DAC treatment influencing cell-cycle progression.
Finally, we also showed that aberrant methylation of Wnt antagonists has a prognostic impact in patients 60 years and younger with intermediate-risk cytogenetics. AML is a heterogeneous disease with different clinical behaviors, of which cytogenetics is the most important prognostic factor. However, the so-called intermediate-risk group comprises a heterogeneous group of patients with apparently normal karyotypes or patients with a variety of other aberrations whose prognostic outcome is uncertain. Therefore, better identification of prognostic indicators in this group has been of particular interest in the past few years. FLT3 mutations have appeared as an important unfavorable prognostic factor in this subgroup, allowing the classification of this vast group of AML patients with normal karyotype into two categories with distinct responses to treatment. 37 Our data show that the methylation profile of Wnt antagonists together with FLT3 mutations is a new poor prognostic factor in the subgroup of patients 60 years and younger with intermediate-risk cytogenetics.
In summary, we demonstrated that methylation of Wnt antagonist genes is frequently observed in AML samples and is associated with activation of the Wnt signaling pathway, conferring an independent poor prognostic impact. The observation that treatment with DAC permits the reexpression of Wnt antagonists and the subsequent inactivation of the Wnt signaling pathway suggests that the use of hypomethylating agents (for example, azacytidine or decitabine) might be beneficial in this subset of AML patients.
